Colossal spinout Astromech raises $20M at $3.8B valuation as AI biotech heats up
MaxUnfried · x · 2026-08-21
Astromech, a spinout of Colossal Biosciences (valued at $12B), announced a $20M raise at a $3.8B valuation. In an interview, CEO Ben Lamm discussed woolly mice, dire wolves, and AI-driven biotech, predicting a "Precambrian explosion" of AI-designed drugs and therapies, and calling Colossal "one of the most undervalued companies in the world."
The thesis rests on a biological gap: up to 50% of biodiversity could be lost in 25 years, and while Asian elephants get cancer at 2–3%, humans do at 24–25%. Colossal has raised $635M total, with every round 2X oversubscribed per Lamm.
Related event: Astromech, Colossal Spinout, Raises $20M at $3.8B Valuation(2 posts)→
More from AGI Musings
- Interp researcher pushes back: if you can't simulate a neuron, you haven't explained it — nabla_theta · 2026-10-16
- Virtue ethics meets AI alignment: what would it mean to make a model virtuous? — joelbot3000 · 2026-10-16
- Professor: this rec letter season I'm evaluating the student plus Claude — RoozbehMottaghi · 2026-10-16
- Prediction: Riemann Hypothesis likely falls to AI before 2030 — gautamcgoel · 2026-10-16
- Models are superintelligent where data is abundant, and weaker everywhere else — burny_tech · 2026-10-16
- ChatGPT's Dot Reviewed: Your Chief of Staff Is Still Just a Codex Wrapper — infinitely_zero · 2026-10-16